Rexulti, Advertising Profile, See Their Ad Spend!

Rexulti Approved by FDA for Major Depressive Disorder and Schizophrenia

Agency 100 2023: MRM for Health

Digital Ads Benchmark Report By Tinuiti, Q2 2023

An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants

Editorial Board

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America

The Madness of Pop Psychiatry - by Nick Jikomes, PhD

How Marketers Accentuate Clinical Messaging

Pre Mid-Terms: Political Ads Capture Attention

FDA approves Rexulti for agitation tied to Alzheimer's dementia, Daily therapy is first to be approved for this use in US

Rexulti Commercial (2022)